Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Other Non-Current Liabilities (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Other Non-Current Liabilities for 6 consecutive years, with $278000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 90.41% to $278000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $278000.0, a 90.41% increase, with the full-year FY2024 number at $135000.0, changed N/A from a year prior.
  • Other Non-Current Liabilities was $278000.0 for Q3 2025 at TScan Therapeutics, up from $113000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $278000.0 in Q3 2025 to a low of $12000.0 in Q3 2023.
  • A 5-year average of $118600.0 and a median of $97000.0 in 2021 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: tumbled 87.63% in 2023, then soared 1116.67% in 2024.
  • TScan Therapeutics' Other Non-Current Liabilities stood at $97000.0 in 2021, then tumbled by 49.48% to $49000.0 in 2022, then crashed by 75.51% to $12000.0 in 2023, then soared by 1025.0% to $135000.0 in 2024, then skyrocketed by 105.93% to $278000.0 in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Other Non-Current Liabilities are $278000.0 (Q3 2025), $113000.0 (Q2 2025), and $124000.0 (Q1 2025).